# Treatment With Pazopanib for Neoadjuvant Breast Cancer

> **NCT00849472** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 101 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** doxorubicin + cyclophosphamide
- **DRUG:** paclitaxel + pazopanib
- **PROCEDURE:** surgery
- **DRUG:** pazopanib monotherapy

## Key facts

- **NCT ID:** NCT00849472
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-12
- **Final completion:** 2013-04
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2014-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849472, "Treatment With Pazopanib for Neoadjuvant Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00849472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*